Our precision therapy programs use genomics to understand how an individual’s genes affect their response to medication and targeted treatments.
GenoRxTM Program: Through pharmacogenomics (PGx), we use genomics to understand how an individual’s genes affect their response to medication. These gene variations can be found through PGx testing so providers can improve medication efficacy and minimize adverse drug reactions. Learn more.
Biomarker Testing Program: If a patient develops cancer, our precision oncology program provides Comprehensive Genomic Profiling (CGP) tests to diagnose genetic anomalies in the tumor for targeted therapy. This information helps us guide actionable and personalized treatment plans—both approved and investigational, including clinical trial recommendations. Learn more.
The Providence Molecular Tumor Board (PMTB) is a systemwide resource to help caregivers with challenging molecular oncology cases. Caregivers use advanced technology to streamline their cases and review them virtually with experts in oncology, anatomic and molecular pathology, genomics, cancer genetics, pharmacology, and clinical research across Providence, who address clinical questions and discuss the therapeutic relevance of variants identified in a patient's tumor, clinical trial considerations, and issues related to the diagnostic and prognostic significance of molecular findings.
Precision4ME Program: This cancer genetics program helps turn a patient’s genetic information into a personalized treatment advantage. Precision4ME uses AI to continuously scan pathology reports to proactively identify cancer patients who meet the National Comprehensive Cancer Network (NCCN) and other established criteria for germline genetic testing. After verification by genetic counselors, eligible patients are invited to take the online Precision4ME assessment to understand their personal and family members inherited cancer risks and consider genetic testing options. With this information, their care team can unlock targeted therapy options and create a personalized, precision medicine treatment plan. Learn more
“On average 20% of people with an identified diagnosis of cancer patients will test positive for an inherited mutation. Using Precision4ME to assess a cancer patient’s inherited cancer risk enables caregivers to personalize treatment plans that benefit the cancer patient and their loved ones.”
"When faced with rare tumors and complex decision-making, Providence Genomics has been a valuable resource to help me provide personalized and cutting-edge care to my patients."
.jpeg)
Stay up to date on our research by following some of our primary researchers:
